Contact Us
Drug Search Results
More Filters [+]

Piclidenoson

Alternative Names: piclidenoson, cf101, cf-101, cf 101
Latest Update: 2024-09-24
Latest Update Note: News Article

Product Description

Piclidenoson is an orally bioavailable, adenosine A3 receptor (A3AR) agonist with potential anti-inflammatory activity. Upon administration, piclidenoson selectively targets, binds to and activates the cell surface-expressed A3AR, thereby activating transduction pathways in which A3AR plays a key role.

Mechanisms of Action: ADORA3 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Ewopharma AG
Company Location:
Company CEO:
Additonal Commercial Interests: Can-Fite BioPharma

Clinical Description

Map of Global Clinical Trials for Piclidenoson

Countries in Clinic: Bosnia, Bulgaria, Canada, Croatia, Israel, Moldova, Poland, Romania, Serbia

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Psoriasis

Phase 2: COVID-19

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CF101-301PS

P3

Completed

Psoriasis

2022-04-28

CF101-241COVID-19

P2

Completed

COVID-19

2022-03-06

24%
2021-002009-85

P2

Completed

COVID-19

2022-01-06

CF101-301PS

P3

Completed

Psoriasis

2022-01-06

58%

Recent News Events

Date

Type

Title

09/24/2024

News Article

 Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis

08/09/2024

News Article

 OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

08/08/2024

News Article

 Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

07/29/2024

News Article

 Can-Fite Provides Namodenoson Patent Update

04/16/2024

PubMed

 Cryo-EM structures of adenosine receptor A3AR bound to selective agonists.

01/26/2024

PubMed

 Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1).

06/01/2023

PubMed

 New synthetic pharmacotherapeutic approaches to the treatment of moderate-to-severe plaque psoriasis in adults.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions